All In Biotech

NDA 218475 · Baxter Hlthcare Corp

Epinephrine Bitartrate In 0.9% Sodium Chloride

Epinephrine Bitartrate · Intravenous

Last checked: Nov 20, 2026Latest source record: Feb 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Feb 28, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

933

108 Phase 3, 77 recruiting

FAERS reports

42,335

26,333 serious, 3,545 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 19, 2026.

Epinephrine in 0.9% Sodium Chloride Injection is a non-selective alpha- and beta-adrenergic agonist indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. ( 1.1 ) 1.1 Hypotension associated with Septic Shock Epinephrine in 0.9% Sodium Chloride Injection is indicated to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.

Mechanism: Epinephrine acts on both alpha (α)- and beta (β)-adrenergic receptors. The mechanism of the rise in blood pressure is 3-fold: a direct myocardial stimulation that increases the strength of ventricular contraction (positive inotropic action), an increased heart rate (positive chronotropic action), and peripheral vasoconstriction.

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 28, 2025 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetter
3 products under this application
  • EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE · EPINEPHRINE BITARTRATE EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE · EPINEPHRINE BITARTRATE EQ 16MG BASE/250ML (EQ 64MCG BASE/ML) · SOLUTION, INTRAVENOUS · Discontinued
  • EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE · EPINEPHRINE BITARTRATE EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Epinephrine Bitartrate" as an intervention, any sponsor and status, largest first.

All 933 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,536
  • headache3,074
  • sinusitis2,919
  • fatigue2,801
  • product dose omission issue2,780
  • pain2,488
  • covid-192,424
  • dyspnoea2,269
  • nausea2,230
  • pneumonia2,076
  • off label use2,065
  • inappropriate schedule of product administration1,785

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004133
2005118
2006136
2007166
2008194
2009269
2010261
2011702
2012425
2013301
2014411
2015635
20161,057
20171,572
20182,477
20193,337
20206,460
20213,909
20223,582
20233,781
20244,431
20254,735
20263,240

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1 on PubMed

Sponsor: Baxter Hlthcare Corp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.